Nasdaq:US$15.40 (+0.01) | HKEX:HK$24.46 (+0.26) | AIM:£2.34 (+0.05)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors